key: cord-0968821-2ud4fwch authors: Achard, Vérane; Aebersold, Daniel M.; Said Allal, Abdelkarim; Andratschke, Nicolaus; Baumert, Brigitta G.; Thomas Beer, Karl; Betz, Michael; Breuneval, Thomas; Bodis, Stephan; de Bari, Berardino; Förster, Robert; Franzetti-pellanda, Alessandra; Guckenberger, Matthias; Herrmann, Evelyn; Huck, Constance; Khanfir, Kaouthar; Matzinger, Oscar; Peguret, Nicolas; Pesce, Gianfranco; Martin Putora, Paul; Reuter, Christiane; Richetti, Antonella; Vees, Hansjörg; Vrieling, Conny; Zaugg, Kathrin; Zimmermann, Frank; Zwahlen, Daniel R.; Tsoutsou, Pelagia; Zilli, Thomas title: A national survey on radiation oncology patterns of practice in Switzerland during the COVID-19 pandemic: present changes and future perspectives date: 2020-06-06 journal: Radiother Oncol DOI: 10.1016/j.radonc.2020.05.047 sha: 72a6df7060e2252e3b7d4868c6a6cac6de9fc0d2 doc_id: 968821 cord_uid: 2ud4fwch • We conducted a Swiss survey on patterns of practice during COVID-19 pandemic. • Dedicated IT solutions were implemented in all radiation-oncology departments. • Upfront endocrine treatments for breast and prostate cancer were privileged. • Use of hypofractionation for breast, rectal cancer and palliation was increased. Funding: None The outbreak of the novel coronavirus disease-19 (COVID-19) has rapidly and drastically impacted worldwide the healthcare system. Despite an increasing number of recommendations becoming available in the last two months, measures adopted in radiation-oncology departments to overcome this situation are rapidly changing and may differ largely based on institutional and national practices. We conducted a national survey of all radiation oncology centers in Switzerland to better understand the early impact of the COVID-19 pandemic on our discipline. A 53-questions online survey was finalized on April 6 th , 2020 using available recommendations [1] [2] [3] [4] [5] [6] [7] [8] and distributed by email on April 07 th , 2020 to the representatives of the 30 Swiss radiation oncology departments. The survey was finalized on April 24 th , 2020 with answers from 22 out of 30 Swiss radiation oncology departments (Suppl. Fig. 1 ). Up to April 7 th , 2020, approximately half (45%, 10/22) of the Swiss radiation-oncology departments had been confronted with patients diagnosed with COVID-19, with 73% of the centers (16/22) experiencing a reduction of their daily activity (suppl. Fig. 1 intact breast and post-mastectomy and/or regional nodal irradiation) (Fig. 1A) . Extreme hypofractionated schedules (i.e., 26 Gy/5 fx daily or 28.5 Gy/5 fx once-weekly, as per the FAST and FAST Forward trials, respectively [9, 10] were adopted in one center (5%). Short course radiotherapy was the preferred neoadjuvant treatment for rectal cancer, with a 23% increase during the pandemic (from 41%, 9/22 to 64%, 14/22) (Fig. 1B) . For other disease sites, with the exception of palliative radiotherapy for symptomatic bone metastases, no clear change of practice was observed (Fig. 2 ). This survey provides a snapshot of the April 2020 status of the Swiss radiation oncology departments following the COVID-19 outbreak and highlights three major aspects. First, confronted with the current pandemic, all radiation oncology departments were able to rapidly implement telemedicine. Second, all centers were able to reorganize institutional practices, with creation of zoning and use of dedicated protective equipment for patients and medical staff. Third, delay of radiotherapy treatments with hormonal manipulations when possible, associated with an increased use of hypofractionation for breast, rectal cancer and palliation were the pragmatic responses of the majority of the centers to the pandemic. Our work faces the limitation associated with reporting the evolution of radiation oncology practices in the earliest stages of the pandemic, when ASTRO/ESTRO recommendations for lung and head and neck cancer [11, 12] were not yet published, with an unequal number of online resources available for participants depending on when they answered the survey (Suppl. Fig. 3 ). Moreover, a single country survey risks to be influenced by several aspects, including national-specific clinical practices, the healthcare reimbursement system, and the influence of governmental legislations undertaken during the pandemic. Nevertheless, valuable information is emerging from this report which may provide basis to better understand the actual and future impact of COVID-19 pandemic on our discipline. Hospitals are marked with a red pinpoint. One university hospital and two satellite centers. Aarau and Baden. Cities in bold refer to radiation oncology departments confronted to COVID-19 patients up to the 7 th April, 2020. Suppl. Figure 2 : Rate of COVID-19 positive patients ( Fig. 2A) and estimated reduction of daily activity ( Fig 2B) in the Swiss radiation oncology departments on April 7 th , 2020. Suppl. Figure 3 : Total published ASTRO/ESTRO papers on COVID-19 over time versus COVID-19 deaths in Switzerland [13] . In green bars, numbers of survey participants per survey date completion. COVID-19 rapid guideline: delivery of radiotherapy. NICE guideline Adapting Radiation Therapy Treatments for Patients with Breast Cancer During the COVID-19 Pandemic: Hypo-Fractionation and Accelerated Partial Breast Irradiation to Address World Health Organization Recommendations Breast radiotherapy under COVID-19 pandemic resource constraints --approaches to defer or shorten treatment from a Comprehensive Cancer Center in the United States International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic Recommendations for Prioritization, Treatment and Triage of Breast Cancer Patients During the COVID-19 Pandemic: Executive Summary International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic Palliative Radiotherapy for Oncologic Emergencies in the setting of COVID-19: Approaches to Balancing Risks and Benefits. Advances in Radiation Oncology Prostate Cancer Radiotherapy Recommendations in Response to COVID-19 First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement htlm  We conducted a Swiss survey on patterns of practice during COVID-19 pandemic  Dedicated IT solutions were implemented in all radiation-oncology departments  Upfront endocrine treatments for breast and prostate cancer were privileged  Use of hypofractionation for breast Acknowledgements: The authors wish to thank the all the members of the Society of Swiss Radiation Oncologists (SRO) and the Scientific Association of Swiss Radiation Oncology (SASRO) for their contribution to this work.All data generated and analyzed during this study are included in this published article